Annals of Hematology

, Volume 97, Issue 10, pp 1803–1808 | Cite as

Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events

  • Matteo MolicaEmail author
  • Emilia Scalzulli
  • Gioia Colafigli
  • Danilo Alunni Fegatelli
  • Fulvio Massaro
  • Roberto Latagliata
  • Robin Foà
  • Massimo Breccia
Original Article


We investigated the median estimated glomerular filtration rate (eGFR) changes in chronic myeloid leukemia (CML) patients treated front line with tyrosine kinase inhibitors (TKIs). A large cohort of 397 patients—320 treated front line with imatinib, 25 with dasatinib, and 53 with nilotinib—was retrospectively analyzed at a single institution. The eGFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation for all patients at baseline and then at 6 and 12 months, and at the last follow-up. Taking into account eGFR changes during the first year of treatment and excluding other possible cardiovascular risk factors, we considered also the percentage of cardiovascular events in patients with modifications of this single parameter. Imatinib induced a decrease in median eGFR (p = 0.01): 42 patients treated with imatinib had a cardiovascular event, related to modification of eGFR, in the absence of other cardiovascular risk factors. In patients treated with nilotinib, the median eGFR did not decline from baseline: only 1 patient experienced an ischemic event, but the eGFR remained unchanged. In patients treated with dasatinib, the mean eGFR did not change significantly: 3 patients experienced a cardiac ischemic event, but in all patients the eGFR remained unchanged over time, while advanced age and metabolic alterations contributed to the ischemic events. This long-term follow-up has documented that imatinib may induce changes in the eGFR, which may contribute to the onset of ischemic events. Further analyses on larger series of CML patients are required to conclusively define the potential renal toxicity of second generation TKIs and the consequent risk of developing ischemic events.


Chronic myeloid leukemia Estimated glomerular filtration Cardiovascular events 


Authors’ contribution

MB designed the study and wrote the manuscript; MM collected data and wrote the manuscript; DAF analyzed data; ES, MC, GC, FM, and RL followed patients; and RF critically revised the paper and approved the final version.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Jabbour E, Deininger M, Hochhaus A (2011) Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25(2):201–210CrossRefGoogle Scholar
  2. 2.
    Pou M, Saval N, Vera M, Saurina A, Solé M, Cervantes F, Botey A (2003) Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 44(7):1239–1241CrossRefGoogle Scholar
  3. 3.
    Barta VS, Uppal NN, Pullman JM, Levy AT, Jhaveri KD (2017) Acute tubular injury associated with imatinib (Gleevec): a case report and review of the literature. J Onco-Nephrol 1(1):57–61CrossRefGoogle Scholar
  4. 4.
    Marcolino MS, Boersma E, Clementino NC et al (2011) Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol 22(9):2073–2079CrossRefGoogle Scholar
  5. 5.
    Yilmaz M, Lahoti A, O'Brien S, Nogueras-González GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE (2015) Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 121(21):3894–3904CrossRefGoogle Scholar
  6. 6.
    Nakagawa T, Sasahara M, Haneda M, Kataoka H, Nakagawa H, Yagi M, Kikkawa R, Hazama F (1999) Role of PDGF B-chain and PDGF receptors in rat tubular regeneration after acute injury. Am J Pathol 155(5):1689–1699CrossRefGoogle Scholar
  7. 7.
    Takikita-Suzuki M, Haneda M, Sasahara M, Owada MK, Nakagawa T, Isono M, Takikita S, Koya D, Ogasawara K, Kikkawa R (2003) Activation of Src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury. Am J Pathol 163:277–286CrossRefGoogle Scholar
  8. 8.
    Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, Wilson BA, Heller G, Sauter NP (2006) Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354:2006–2013CrossRefGoogle Scholar
  9. 9.
    Levey AS, Stevens LA, Schmid CH, Zhang Y(L), Castro AF III, Feldman HI, Kusek JW, Eggers P, van Lente F, Greene T, Coresh J, for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612CrossRefGoogle Scholar
  10. 10.
    National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 39(2 Suppl 1):S1–S266Google Scholar
  11. 11.
    Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A, Acute Kidney Injury Network (2007) Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11(2):R31CrossRefGoogle Scholar
  12. 12.
    Floege J, Eitner F, Alpers CE (2008) A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 19(1):12–23CrossRefGoogle Scholar
  13. 13.
    Kishioka H, Fukuda N, Wen-Yang H et al (2001) Effects of PDGF A-chain antisense oligodeoxynucleotides on growth of cardiovascular organs in stroke-prone spontaneously hypertensive rats. Am J Hypertens 14(5 Pt 1):439–445CrossRefGoogle Scholar
  14. 14.
    Zoja C, Corna D, Rottoli D, Zanchi C, Abbate M, Remuzzi G (2006) Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int 70(1):97–103CrossRefGoogle Scholar
  15. 15.
    Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ (1992) Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci U S A 89(7):2873–2877CrossRefGoogle Scholar
  16. 16.
    Lassila M, Allen TJ, Cao Z et al (2004) Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol 24(5):935–942CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto ISapienza UniversityRomeItaly
  2. 2.Department of Statistical Sciences, Policlinico Umberto ISapienza UniversityRomeItaly

Personalised recommendations